A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
OncoC4, Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Imugene Limited
AstraZeneca
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
University of Florida
DualityBio Inc.
Big Ten Cancer Research Consortium
Genfit
State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
RenJi Hospital
City of Hope Medical Center
Actym Therapeutics, Inc.
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC
Minia University
Elicio Therapeutics
University of Colorado, Denver
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Leap Therapeutics, Inc.
Region Stockholm
Oslo University Hospital
University Hospital, Ghent
Shanghai Bao Pharmaceuticals Co., Ltd.
Shandong Cancer Hospital and Institute
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
Pfizer
Göteborg University
Elevation Oncology
University of Leipzig
Beth Israel Deaconess Medical Center
Intensity Therapeutics, Inc.
PureTech
Alliance for Clinical Trials in Oncology
Erbe Elektromedizin GmbH
Insel Gruppe AG, University Hospital Bern
Ohio State University Comprehensive Cancer Center
Carisma Therapeutics Inc
University of Pittsburgh
Beijing Biostar Pharmaceuticals Co., Ltd.
M.D. Anderson Cancer Center
UTC Therapeutics Inc.
Seoul National University Hospital